Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Autonomic Dysregulation in Multiple Sclerosis.
Variations in predicted risks in personal genome testing for common complex diseases.
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.
Olanzapine ameliorates neuropathological changes and increases IGF-1 expression in frontal cortex of C57BL/6 mice exposed to cuprizone.
The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice.
What's in the Literature?
Artificial antigen presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4+ T cells.
FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.
P2X Receptors as Drug Targets.
Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells.
The Influence of T Cell Ig Mucin-3 Signaling on Central Nervous System Autoimmune Disease Is Determined by the Effector Function of the Pathogenic T Cells.
Fingolimod therapy for multiple sclerosis.
Current and emerging therapies for multiple sclerosis.
Muscle oxygen consumption by NIRS and mobility in multiple sclerosis patients.
Errors in the Byline, Author Affiliations, and Author Contributions in: Long-term Follow-up of Acute Partial Transverse Myelitis.
FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway.
Analysis of HLA-DQB1*0602 in Multiple Sclerosis Patients in Khuzestan Province, Iran.
Perspectives on cytokine-directed therapies in multiple sclerosis.
Heatlh Care Costs Associated with Patients Diagnosed with Relapsing Remitting Multiple Sclerosis Taking Once Daily Teriflunomide Tablets in the United States.
Prevalence of multiple sclerosis among immigrants in Norway.
Regulatory Effect of 25-hydroxyvitamin D3 on Nitric Oxide Production in Activated Microglia.
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.
Assessing risks of multiple sclerosis therapies.
Multimodal imaging of subventricular zone neural stem/progenitor cells in the cuprizone mouse model reveals increased neurogenic potential for the olfactory bulb pathway, but no contribution to remyelination of the corpus callosum.
Does long-term partial sodium channel blockade alter disease progression in MS? Evidence from a retrospective study.
Pages
« first
‹ previous
…
541
542
543
544
545
546
547
548
549
…
next ›
last »